<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940603-1-00010</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> : Written comments by August 17, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4702 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Parts 600, 601, and 610</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 94N&hyph;0066]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Review of General Biologics and Licensing Regulations <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Intent to review regulations; request for comments. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is conducting a review of certain general biologics and licensing regulations and is requesting public comment on these regulations. This review is intended to identify regulations that are outdated, burdensome, inefficient, or otherwise unsuitable or unnecessary from a regulatory standpoint and in need of revision. This review is part of FDA's program to periodically review existing significant regulations. A request for comments on certain regulations for blood establishments and blood products will be published elsewhere in this issue of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> . <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> : Written comments by August 17, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> : Submit written comments to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Ann Reed Gaines or Timothy W. Beth, Center for Biologics Evaluation and Research (HFM&hyph;635), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852&hyph;1448, 301&hyph;594&hyph;3074. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> : In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  of January 20, 1994 (59 FR 3043), FDA announced its plan to review significant regulations pursuant to Executive Order 12866, which requires all Federal agencies to develop a program for periodically reviewing existing significant regulations. Under this plan, FDA is conducting a review of the general biologics and licensing regulations in 21 CFR parts 600, 601, and 610, and is requesting public comment on these regulations.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> FDA is conducting a review of these regulations to determine whether they should be revised, rescinded, or continued without change. FDA is also evaluating whether to review other regulations applicable to biological products. This request for comments is intended to assist the Center for Biologics Evaluation and Research in identifying regulations that are outdated, burdensome, inefficient, or otherwise unsuitable or unnecessary from a regulatory standpoint and in need of revision to achieve their public health goals more effectively. Under Executive Order 12866, the Paperwork Reduction Act of 1980 (Pub. L. 96&hyph;511), and the Regulatory Flexibility Act (Pub. L. 96&hyph;354), FDA is performing this review of these existing regulations to determine whether they are unnecessary as a result of changed circumstances, duplicative, or inappropriately burdensome. This action is also intended to incorporate the scientific advances in the field, to introduce, where appropriate, increased flexibility in the regulations, and to further insure the safety, purity, and potency of biologics products by updating the regulations. This document requests public comment on these regulations.  <!-- PJG 0012 frnewline --> A request for comments on the blood establishments and blood products regulations in 21 CFR parts 606, 607, 610, 640, and 660 will be published elsewhere in this issue of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . <!-- PJG 0012 frnewline --> Interested persons may, on or before August 17, 1994, submit to the Dockets Management Branch (address above) written comments regarding this request. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. FDA requests that comments include the following information in the order shown: (1) The section affected in Title 21 of the CFR; (2) a description of the change suggested, including, if appropriate, suggested changes in the text of the regulation; (3) the rationale for the change or the problem to be addressed by the change; (4) any related regulations or guidance also affected by the suggested change; (5) any pertinent background information; and (6) whether the comment includes attachments. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: May 26, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Michael R. Taylor, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;13465 Filed 6&hyph;2&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            